Invizyne (IZTC) - יחס שווי פעילות לרווח לפני ריבית, מסים ופחת

Invizyne Technologies Inc. (IZTC) previously relied on creating cell-free systems for the cosmetics industry, which created commercial risks. The change in the company's EV/EBITDA level on the GURU.Markets chart demonstrates current dynamics, where the metric is fixed at . Management is now implementing scalable synthesis to reduce costs, while the unique SimpleCell platform provides significant pricing power in biopharmaceuticals.

For Invizyne Technologies Inc. (IZTC), whose enzymatic synthesis patents require colossal capital expenditures, analyzing business value relative to operating profit is critical. The company's EV/EBITDA ratio on this chart compares the total market value of the asset with its ability to generate cash flow before interest, taxes, depreciation, and amortization. An increase in this metric amid stagnant earnings would indicate a dangerous inflation of liabilities, calling into question the financial stability of its high-tech production.